Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug
Masashi Okada(Yamagata University), Chifumi Kitanaka(Yamagata University)
Cited by 37
Related Papers
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells
|Stem Cells|2010|219
Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells
|Oncotarget|2014|196
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
|Oncotarget|2014|94
Physical and functional interaction between BH3-only protein Hrk and mitochondrial pore-forming protein p32
|Cell Death and Differentiation|2004|76